Hemadri Cements Intrinsic Value
Hemadri Cements intrinsic value. Hemadri Cements (HEMACEM) median intrinsic value is ₹26.53 from 2 valuation models (range ₹15–₹27), vs current price ₹50.88 — -47.9% downside (Trading Above Calculated Value), margin of safety -91.8%. Compare with Hemadri Cements valuation methods to assess whether the stock is under or overvalued.
HEMACEM Valuation Methods Summary — DCF, Graham Number & P/E
Hemadri Cements intrinsic value across 2 models vs current price ₹50.88 — upside/downside and value range per method. For current market price and key ratios, visit HEMACEM share price.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹15.26 | ₹13.73 - ₹16.79 | -70.0% | Revenue/Share: ₹1.43, P/S: 0.8x |
| Simple DCF (5Y) | dcf | ₹26.53 | ₹21.22 - ₹31.84 | -47.9% | CF Growth: 5.0%, Discount: 15% |
HEMACEM Intrinsic Value vs Market Price — All Valuation Models
Hemadri Cements fair value range ₹15–₹27 vs current market price ₹50.88 across 2 valuation models. Read HEMACEM ex-dividend dates for the complete payout history and dividend yield track record.
HEMACEM Intrinsic Value Analysis — Undervalued or Overvalued?
Hemadri Cements median intrinsic value ₹26.53, current price ₹50.88 — Trading Above Calculated Value by 47.9%, margin of safety -91.8%.
What is the intrinsic value of HEMACEM?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Hemadri Cements (HEMACEM) is ₹26.53 (median value). With the current market price of ₹50.88, this represents a -47.9% variance from our estimated fair value.
The valuation range spans from ₹15.26 to ₹26.53, indicating ₹15.26 - ₹26.53.
Is HEMACEM undervalued or overvalued?
Based on our multi-method analysis, Hemadri Cements (HEMACEM) appears to be trading above calculated value by approximately 47.9%.
HEMACEM Financial Health — Key Ratios vs Industry Benchmarks
Hemadri Cements financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.52 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | -6.00 | Industry Standard: <0.5 | Below 0.5 | Indicates financial leverage level |
| Return on Equity | 475.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.04x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
HEMACEM Cash Flow Quality — Operating & Free Cash Flow
Hemadri Cements operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-11 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-5 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹12 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2020 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |